INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. regarding potential securities fraud or unlawful business practices [1] - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director, leading to a suspension of its full-year 2025 financial guidance [3] - Following the leadership change announcement, agilon's stock price dropped by $0.93, or 51.51%, closing at $0.88 per share on August 5, 2025 [3] Company Developments - The investigation by Pomerantz LLP focuses on whether agilon and its officers/directors engaged in misconduct [1] - The leadership change at agilon is part of a broader evaluation of actions to optimize operating performance amid market uncertainty [3] - The suspension of financial guidance indicates potential challenges in achieving previously set performance targets [3]